Abstract
In the AEGEAN study, the addition of an education program to apixaban therapy in patients with atrial fibrillation did not improve patient adherence or persistence to therapy at 24 weeks. The rates of adherence and persistence were high.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
